PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07D 239/94, A61K 31/505, C07D 401/04, 403/04, 405/04, 407/04, 409/04, 411/04, 413/14, 409/12, 411/12, 403/12, 401/12, 407/12, 409/14

A1

(11) International Publication Number: WO 97/30034

(43) International Publication Date: 21 August 1997 (21.08.97)

(21) International Application Number: PCT/GB97/00344

(22) International Filing Date: 10 February 1997 (10.02.97)

(30) Priority Data:
9603095.2 14 February 1996 (14.02.96) GB

(71) Applicant: ZENECA LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB).

(72) Inventors: BARKER, Andrew, John; Zeneca Pharmaceuticals, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). JOHNSTONE, Craig; Zeneca Pharmaceuticals, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(74) Agent: TAIT, Brian, Steele; Zeneca Pharmaceuticals, Intellectual Property Dept., Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS

(57) Abstract

The invention concerns quinazoline derivatives of formula (I), wherein X^1 is a direct link or a group such as CO, $C(R^2)_2$ and $CH(OR^2)$; wherein Q^1 is phenyl, naphthyl or a 5- or 6-membered heteroaryl moiety and Q^1 optionally bears up to 3 substituents; wherein m is 1 or 2 and each R^1 may be a group such as hydrogen, halogeno and trifluoromethyl; and wherein Q^2 may be phenyl or a 9- or 10-membered bicyclic heterocyclic moiety and Q^2 optionally bears up to 3 substituents; or a pharmaceutically acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and the use of their receptor tyrosine kinase inhibitory properties in the treatment of proliferative disease such as cancer.



(I)